TNXP at a glance
Tonix Pharmaceuticals Holding Corp. (TNXP, SEC CIK 1430306) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as August 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $13.1 million (up 29.8% from FY2024) and a net loss of $124.0 million. Diluted EPS was -$14.57.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Tonix Pharmaceuticals Holding Corp. (TNXP) shares worth $64.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by LEDERMAN SETH on August 27, 2026 of 2,000 shares at $13.79 per share.
- In the last 90 days, TNXP insiders reported 2 open-market purchases ($40K) and 0 open-market sales ($0) on Form 4, a net purchase of $40K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.1M
- +29.8% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$40K
- 13F holders
- 21 funds
- $64.6M · +3 vs prior quarter
- Latest 8-K
- Sep 22, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $13.5M vs $2.0M, up $11.5M YoY, driven by TONMYA launch
- TONMYA best-performing product, $11.0M revenue; Tosymra lowest, $0.6M
- Operating loss $42.5M vs $28.3M; net loss $40.6M vs $28.3M
- Cash $176.2M at June 30; operating cash use $84.6M vs $31.4M YoY
- Funding outlook: resources expected through early Q2 2027, with substantial going-concern doubt beyond one year
Risk Factors
- No material changes identified; risks cross-referenced to December 31, 2025 Form 10-K
- Additional unknown or currently immaterial risks potentially affecting financial position, results, or cash flows
- No new regulatory or compliance risk disclosed for quarter ended June 30, 2026
- No equity sales, securities purchases, or senior-security defaults during the quarter
AI summary of the TNXP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- TONMYA coverage added for approximately 21 million Medicare Part D beneficiaries through a pharmacy benefit manager
- Total government and commercial coverage now reaches approximately 166 million individuals
Item EX-99.1: Item EX-99.1
- Second managed Medicare agreement effective immediately, adding approximately 21 million covered lives
- Medicare coverage reaches 32 million lives, or 58% of approximately 55 million U.S. Medicare lives
Item 8.01: Other Events
- Thomas Englese appointed Chief Commercial Officer effective September 8, 2026
- Commercial leadership addition potentially signals preparation for product launches or expanded commercialization
Item EX-99.1: Item EX-99.1
- Thomas Englese promoted to Chief Commercial Officer effective immediately, formalizing leadership of Tonix’s commercial organization
- Continued responsibility for sales, marketing, market access, and operations across TONMYA, Zembrace SymTouch, and Tosymra
AI summaries of TNXP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TNXP
Don't miss the next TNXP filing
- Alerts as it files. A push when TNXP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TNXP, by share count.
- Ask anything. An AI agent that reads every TNXP filing and answers with sources.
TNXP alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LEDERMAN SETH | Buy | Aug 27, 2026 | 2,000 | $13.79 |
| BAGGER RICHARD H | Buy | Aug 20, 2026 | 1,000 | $12.60 |
| SAENGER BRADLEY | J | Jun 30, 2026 | 1,453 | $10.91 |
| Taylor Carolyn E. | Buy | Jun 12, 2026 | 1,415 | $10.55 |
| LEDERMAN SETH | Buy | Jun 9, 2026 | 5,000 | $11.79 |
| Stillwell Richard Newcomb | Buy | Jun 8, 2026 | 5,000 | $11.65 |
| Taylor Carolyn E. | A | May 12, 2026 | 22,700 | - |
| BAGGER RICHARD H | A | May 12, 2026 | 22,700 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.1M | $13.1M |
| Operating Income | -$118.4M | -$136.7M | -$125.7M |
| Net Income | -$116.7M | -$130.0M | -$124.0M |
| Op. Margin | - | -1354.3% | -959.1% |
| Net Margin | - | -1288.3% | -946.2% |
| Balance Sheet | |||
| Total Assets | - | $162.9M | $277.2M |
| Equity | - | $139.6M | $245.2M |
| ROE | - | -93.2% | -50.6% |
| Per Share | |||
| EPS | - | $-176.60 | $-14.57 |
| Cash Flow | |||
| Operating CF | -$102.0M | -$60.9M | -$99.8M |
| CapEx | $7.9M | $120K | $3.4M |
Source: XBRL data in Tonix Pharmaceuticals Holding Corp. (TNXP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TNXP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $64.6M |
| Q1 2026 | 18 | $40.6M |
| Q4 2025 | 16 | $33.8M |
| Q3 2025 | 13 | $41.7M |
| Q2 2025 | 14 | $34.3M |
| Q1 2025 | 6 | $3.0M |
- Millennium Management+747.3K (+340%)
- AQR Capital Management+721.4K (+447%)
- BlackRock+429.9K (+44%)
- Vanguard Capital Management LLC+173.2K (+33%)
- FMR LLC (Fidelity)+91.8K (+5283%)
- Citadel Advisors LLC−272.9K (-58%)
- Morgan Stanley−2.0K (-12%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 88 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TNXP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 21, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| SC 13G | Jun 15, 2026 | - | - | |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 15, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TNXP SEC filings: frequently asked questions
Are TNXP insiders buying or selling?
In the last 90 days, Tonix Pharmaceuticals Holding Corp. (TNXP) officers, directors and 10% owners reported 2 open-market purchases worth $40,180 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TNXP stock?
As of June 30, 2026, the largest Tonix Pharmaceuticals Holding Corp. (TNXP) holders among the 13F filers tracked by SignalX were BlackRock ($17.8 million), Millennium Management ($12.3 million), AQR Capital Management ($11.3 million), Vanguard Capital Management LLC ($8.8 million), State Street Corp ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TNXP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $13.1 million (up 29.8% from FY2024) and a net loss of $124.0 million. Diluted EPS was -$14.57. The figures come from the XBRL data in the 10-K.
What did TNXP report in its latest 8-K?
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K on September 22, 2026 reporting Item 8.01 (Other Events). TONMYA coverage added for approximately 21 million Medicare Part D beneficiaries through a pharmacy benefit manager.
What are the latest TNXP SEC filings?
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on August 31, 2026.
What is TNXP's SEC CIK number?
Tonix Pharmaceuticals Holding Corp. (TNXP)'s SEC Central Index Key (CIK) is 1430306. EDGAR lists every TNXP filing under that number.
Ask anything about TNXP
The research agent reads TNXP's filings, financials, insider trades and 13F holders, then answers with sources.